We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Kidney Disease Biomarker May Indicate Lung Problems

By LabMedica International staff writers
Posted on 09 Oct 2018
Print article
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Chronic lower respiratory diseases (CLRD) are the fourth leading cause-of-death and a major source of health care costs. CLRD includes chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and asthma, airflow limitation as a physiologic correlate, and acute exacerbations as the major clinical manifestation.

Albuminuria is a commonly used biomarker of endothelial damage in the kidneys and correlates with microvascular dysfunction throughout the body, including in the pulmonary circulation. Cross-sectional studies suggest albuminuria is increased in COPD patients, among whom it is adversely associated with lung function, gas exchange, and hypoxia.

A large team of scientists working with the Columbia University College of Physicians & Surgeons (New York, NY, USA) conducted their study by pooling information from 31,877 participants (average age: 60 years) from six cohort studies. Urine albumin was measured by nephelometry or immunoturbidometry, and urine creatinine assessed by the Jaffe method. These were used to calculate the spot urine albumin-to-creatinine ratio, called “albuminuria.” Pre-bronchodilator lung function was measured using water-seal, dry-rolling-seal, or flow sensing spirometers. Incident moderate-to-severe COPD was defined as FEV1/FVC<LLN and FEV1<80% at the final spirometry exam.

The team reported that they found for each standard deviation increase in albuminuria, there was a 15% increase in those who developed moderate-to-severe COPD; a 26% increase in COPD hospitalizations and deaths; and 3% greater decline in FEV1 (the amount of air that can be forcibly exhaled in one second) and an 11% greater decline in the ratio between FEV1 and FVC (the total amount of air that can be forcibly exhaled after taking the deepest breath possible). Both FEV1 and FEV1/FVC are important measures of lung function.

Elizabeth C. Oelsner, MD, MPH, an Assistant Professor of Medicine and lead author of the study, said, “Our study helps to explain why COPD patients often have a constellation of vascular problems, including heart and kidney disease. This makes it all the more important for clinicians to encourage avoidance of exposures like smoking and treatment of diseases like hypertension and diabetes that cause endothelial dysfunction.” The study was published on September 28, 2018, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Columbia University College of Physicians & Surgeons

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.